Praglandia s.r.o.
- Address
- lock Available on a paid plan
Praglandia s.r.o. - Dermatology & Neuropsychiatric Research Center
Praglandia s.r.o. is a specialized clinical research facility with extensive expertise in dermatological disorders and neuropsychiatric conditions. The center demonstrates particular proficiency in conducting complex Phase 2 and Phase 3 clinical trials, with a strong focus on evaluating novel biologic therapies and small molecule treatments. Their research portfolio encompasses a broad spectrum of therapeutic areas, with significant contributions to understanding treatment mechanisms and long-term safety profiles of innovative medications.
- Atopic Dermatitis: Multiple trials evaluating biologics (GSK1070806, amlitelimab, nemolizumab), novel therapies (LEO 138559, SAR444656, rezpegaldesleukin), and traditional agents (methotrexate) in moderate-to-severe disease
- Psoriasis and Psoriatic Arthritis: Comprehensive studies of ESK-001, TAK-279, zasocitinib, and sonelokimab for both plaque psoriasis and arthritic manifestations
- Migraine Disorders: Preventive and acute treatment trials with novel agents including atogepant, MEDI0618, and Lu AG09222 for episodic and chronic migraine
- Major Depressive Disorder: Innovative adjunctive therapy studies with aticaprant and NBI-1065845, including relapse prevention and anhedonia-focused treatments
The center's research infrastructure supports diverse study designs, from dose-finding trials to long-term extension studies, demonstrating capability in managing complex protocols requiring extended patient follow-up. Additional therapeutic areas include metabolic conditions such as obesity and hypertension with orforglipron studies, and Parkinson's Disease research with CVN424. The center's experience with both biologic-naive populations and comparative effectiveness trials positions them as a valuable contributor to advancing treatment options across multiple therapeutic domains.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 43 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Praglandia s.r.o.
lock Showing 1 of 48 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-509 in Adults with Moderate to Severe Atopic Dermatitis | Triveni Bio Inc. | Phase II | Not Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 43 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 5 | Unknown | 2022-11-10 | 2024-10-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.